Compare KYMR & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYMR | EVR |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.7B |
| IPO Year | 2020 | 2006 |
| Metric | KYMR | EVR |
|---|---|---|
| Price | $122.17 | $291.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 11 |
| Target Price | $139.83 | ★ $332.20 |
| AVG Volume (30 Days) | ★ 745.8K | 529.2K |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | N/A | ★ 54.74 |
| EPS | N/A | ★ 9.56 |
| Revenue | $39,211,000.00 | ★ $3,880,084,000.00 |
| Revenue This Year | $167.19 | $20.37 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ N/A | $27.20 |
| Revenue Growth | N/A | ★ 29.49 |
| 52 Week Low | $55.66 | $245.47 |
| 52 Week High | $130.05 | $388.71 |
| Indicator | KYMR | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | 68.82 |
| Support Level | $110.64 | $280.02 |
| Resistance Level | $128.95 | $300.24 |
| Average True Range (ATR) | 5.03 | 9.80 |
| MACD | 1.50 | 3.27 |
| Stochastic Oscillator | 96.51 | 95.43 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance-sheet lending, allowing it to compete with larger, bulge-bracket banks.